Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedinotecMDNC 24 EV-to-EBITDA is 48.53 as of Aug. 15, 2026, which is 40% above its 10-year median of 34.60. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medinotec's enterprise value is $56.88 Mil.
Medinotec's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was $1.17 Mil. Therefore, Medinotec's EV-to-EBITDA for today is 48.53.
The historical rank and industry rank for Medinotec's EV-to-EBITDA or its related term are showing as below:
MDNC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -323.25 Med: 34.6 Max: 2519.65
Current: 48.53
During the past 5 years, the highest EV-to-EBITDA of Medinotec was 2519.65. The lowest was -323.25. And the median was 34.60.
MDNC's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 14.89
vs MDNC: 48.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medinotec's share price for today is $5.00.
Medinotec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medinotec's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medinotec's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinotec EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medinotec's EV-to-EBITDA falls into.
Medinotec's current Enterprise Value is $56.88 Mil.
Medinotec's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinotec (MDNC) has a EV-to-EBITDA of 48.53 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medinotec. This is 40% above median its historical median of 34.60.
Is Medinotec's EV-to-EBITDA too high?
Medinotec's current EV-to-EBITDA of 48.53 is 40% above median its 10-year median of 34.60. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.89. Medinotec's value of 48.53 is 225.9% above this industry median. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's EV-to-EBITDA compare to NVNO and APYX?
Medinotec's EV-to-EBITDA of 48.53 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-EBITDA is 14.89. Medinotec's value of 48.53 is 225.9% above this benchmark. While the company's 10-year median is 34.60 vs. the industry median of 14.89, Medinotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.89, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinotec's current EV-to-EBITDA of 48.53 is 225.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medinotec. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current EV-to-EBITDA is 48.53, which is 40% above median its own 10-year median of 34.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current EV-to-EBITDA of 48.53. The current EV-to-EBITDA is 48.53, which is 40% above median its 10-year median of 34.60 and 225.9% above the Medical Devices & Instruments industry median of 14.89. Medinotec's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medinotec (MDNC), the current EV-to-EBITDA is 48.53 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score
Get the complete analysis for MDNC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNC has been successfully added to your 
